Search for drugs:
Typing the drug name to query
SECNIDAZOLE
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology
- The effect of secnidazole on the QTc interval was evaluated in a Phase 1 randomized, double blind, placebo- and positive-controlled four-period crossover thorough QTc study in 52 healthy adult subjects following single oral granule doses of 2 g and 6 g (3-times the recommended dose). Although there was a positive relationship of the QTc interval with secnidazole concentrations, there was no clinically relevant increase in the QTc interval following either dose.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
0
24092
Other ADRs
0
38381587
Odds Ratio = N/A
Drug Property Information
ATC Code(s):
- P01AB07 - secnidazole
- P01AB - Nitroimidazole derivatives
- P01A - AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES
- P01 - ANTIPROTOZOALS
- P - "ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS"
- J01RA07 - secnidazole
- J01RA - Combinations of antibacterials
- J01R - COMBINATIONS OF ANTIBACTERIALS
- J01 - ANTIBACTERIALS FOR SYSTEMIC USE
- J - ANTIINFECTIVES FOR SYSTEMIC USE
Active Ingredient:SECNIDAZOLE
Active Ingredient UNII:R3459K699K
Drugbank ID:DB12834
PubChem Compound:71815
CTD ID:C016724
CAS Number:3366-95-8
Dosage Form(s):granule
Route(s) Of Administrator:oral
Daily Dose:
- 2000.0 mg/day P01AB07
Chemical Structure: 
SMILE Code:
CC(O)CN1C(C)=NC=C1N(=O)=O
CC(O)CN1C(C)=NC=C1N(=O)=O
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.